Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
100%
Direct Oral Anticoagulant
57%
Anticoagulant Agent
43%
Antiplatelet
35%
Bleeding
34%
Disease
33%
Acute Coronary Syndrome
33%
Clopidogrel
26%
Clinical Trial
25%
Pharmacodynamics
24%
Atrial Fibrillation
22%
Warfarin
22%
Pharmacokinetics
22%
Acetylsalicylic Acid
21%
Ticagrelor
21%
Antithrombocytic Agent
17%
Rivaroxaban
16%
Prasugrel
15%
Fondaparinux
15%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Antivitamin K
14%
Hip Fracture
13%
Stable Angina Pectoris
13%
Sepsis
13%
Heparin
12%
Thromboembolism
12%
Cardiovascular Disease
12%
Observational Study
12%
Blood Clotting Factor 10a Inhibitor
11%
Pharmacotherapy
11%
Artery Thrombosis
10%
Statin (Protein)
10%
Fibrinogen Receptor
10%
Vein Thrombosis
10%
Apixaban
9%
Thienopyridine
9%
Brain Hemorrhage
9%
Low Molecular Weight Heparin
9%
Adverse Event
9%
Cangrelor
9%
Dabigatran
8%
Coronary Artery Disease
8%
Betrixaban
8%
Randomized Controlled Trial
7%
Enoxaparin
7%
Ischemia
7%
Anticoagulation Therapy
7%
Prevalence
7%
CYP2C19
7%
Edoxaban
7%
Medicine and Dentistry
Venous Thromboembolism
42%
Anticoagulation
38%
Acute Coronary Syndrome
25%
Clinician
21%
COVID-19
20%
Antiplatelet
17%
Direct Oral Anticoagulant
15%
Intensive Care Unit
13%
Coronary Artery Disease
13%
Stable Angina
13%
Prothrombin Complex
13%
Health Care Cost
13%
Health Care
12%
Clinical Trial
12%
Antiplatelet Drug
10%
Bleeding
10%
Fibrinogen Receptor
10%
Cardiovascular Disease
10%
Extracorporeal Membrane Oxygenation
9%
Anticoagulant Therapy
9%
Acetylsalicylic Acid
9%
Cangrelor
9%
Ranolazine
8%
Thromboprophylaxis
8%
Antithrombotic Therapy
8%
Receptor
7%
Ticagrelor
7%
Clopidogrel
7%
Platelet
7%
Drug Therapy
7%
Percutaneous Coronary Intervention
7%
Drug-Eluting Stent
7%
Major Bleeding
6%
Secondary Prevention
6%
Patient with Type 2 Diabetes
6%
Randomized Clinical Trial
6%
ST Elevation
6%
Valve Replacement
6%
Percutaneous Aortic Valve Replacement
6%
Ischemia
6%
Cardioversion
6%
Restenosis
6%
Thrombocyte Aggregation
6%
Coagulopathy
6%
Maturity Onset Diabetes of the Young
6%
Andexanet Alfa
6%
Blood Clotting Factor 10a Inhibitor
6%
Platelet Reactivity
6%
Glycoprotein IIb/IIIa Inhibitors
6%
Cardiovascular System
6%
Keyphrases
Venous Thromboembolism
34%
Direct Oral Anticoagulants
21%
Venous Thromboembolism Prevention
21%
Warfarin
16%
Venous Thromboembolism Prophylaxis
16%
Pharmacology
15%
Anticoagulation
13%
Ticagrelor
13%
Unfractionated Heparin
10%
COVID-19
10%
Pharmacodynamics
9%
Bleeding
9%
Renal Impairment
9%
Medically Ill Patients
8%
Medical Patients
8%
Antithrombotic Therapy
8%
Rivaroxaban
8%
Oral Anticoagulants
8%
Stroke Prevention in Atrial Fibrillation
8%
Thromboprophylaxis
7%
Extended Prophylaxis
6%
Coagulopathy
6%
Acquisition Cost
6%
Hospital Acquisition
6%
Antibiotic Costs
6%
Time Management
6%
Acute Disease
6%
Oral Anticoagulant Therapy
6%
Oral Factor Xa Inhibitors
6%
Antithrombotic Agents
6%
Case-based Approach
6%
Andexanet Alfa
6%
Prothrombin Complex Concentrate
6%
Intermediate Dose
6%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
6%
Native American
6%
CYP2C19
6%
Aspirin
6%
Variant Allele
6%
Transcatheter Aortic Valve Replacement
6%
Clopidogrel
6%
Antiplatelet Therapy
6%
At-risk
6%
Backward Navigation
6%
High-fat Meal
6%
Ximelagatran
6%
Renal Function
6%
In-hospital Mortality
6%
Randomized Trial
6%
Economic Burden
6%
